Skip to main content

MoneyWorks4Me

FDC informs about disclosure

21 Nov 2026 Evaluate

Pursuant to the provisions of Regulation 30 read with Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), FDC has informed that the Company has received an Interim Stay Order from the Hon'ble High Court of Bombay Bench at Aurangabad dated November 20, 2026 staying the Directions of Maharashtra Pollution Control Board (MPCB) directing closure of manufacturing operations of the Company’s unit situated at Plot no. B-8, MIDC, Waluj, Chhatrapati Sambhajinagar under the Water (Prevention and Control of Pollution) Act, 1974 and/or the Air (Prevention and Control of Pollution) Act, 1981, and the rules framed thereunder. The Company had already submitted to MPCB its Compliance Reports on their observations. The requisite disclosure as required under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure I.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..